Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
Type:
Grant
Filed:
July 30, 2021
Date of Patent:
February 27, 2024
Assignee:
SABIN VACCINE INSTITUTE
Inventors:
Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
Abstract: Disclosed herein are methods and platforms for increasing utility and efficacy of a cellular vaccine. Specifically, disclosed are steps that optimize ex vivo B cell expansion and boost host in vivo immunity. Also disclosed is a platform for enhancing effectiveness of antigen presentation and antigen-specific immune responses. Also disclosed is a method for enhancing effectiveness of APCs in a subject. Also disclosed are vaccines and kits based on the platform.
Type:
Grant
Filed:
July 13, 2017
Date of Patent:
December 26, 2023
Assignee:
Ohio State Innovation Foundation
Inventors:
Thomas L Cherpes, Nirk E. Quispe Calla, Rodolfo Daniel Vicetti Miguel
Abstract: Provided are an enterovirus D68 (EV-D68) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the EV-D68 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, or a pharmaceutical composition comprising the EV-D68 or a modified form thereof, or the nucleic acid molecule, and use of the EV-D68 or a modified form thereof, or the nucleic acid molecule in the manufacture of a pharmaceutical composition for treating a tumor.
Type:
Grant
Filed:
July 18, 2018
Date of Patent:
October 24, 2023
Assignees:
XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.
Inventors:
Tong Cheng, Wei Wang, Junkai Wan, Wenkun Fu, Xiangzhong Ye, Jun Zhang, Ningshao Xia
Abstract: A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.
Type:
Grant
Filed:
April 8, 2022
Date of Patent:
October 10, 2023
Assignee:
Kansas State University Research Foundation
Abstract: A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.
Type:
Grant
Filed:
February 19, 2021
Date of Patent:
October 10, 2023
Assignee:
Kansas State University Research Foundation
Abstract: The invention relates to an ex vivo generated population of tissue-specific anti-inflammatory macrophages and methods of making and using such macrophages.
Type:
Grant
Filed:
March 30, 2018
Date of Patent:
September 19, 2023
Assignee:
Wisconsin Alumi Research Foundation
Inventors:
Peiman Hematti, Eric G. Schmuck, John A. Kink, Amish N. Raval
Abstract: The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and live attenuated PRRS virus for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus by administration of the vaccine into the dermis of the animal.
Type:
Grant
Filed:
March 22, 2017
Date of Patent:
May 23, 2023
Assignee:
Intervet Inc.
Inventors:
Melanie Sno, Maarten Hendrik Witvliet, Vicky Fachinger
Abstract: [Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of ?-GalCer loaded on aAVC cell surface, and the amount of ?-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.
Abstract: The present invention provides Factor IX fusion proteins with higher specific activity and a longer useful clotting function relative to wild type or non-modified Factor IX protein.
Type:
Grant
Filed:
October 19, 2016
Date of Patent:
January 24, 2023
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Type:
Grant
Filed:
March 27, 2020
Date of Patent:
November 1, 2022
Assignee:
ModernaTX, Inc.
Inventors:
Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
Abstract: This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
August 2, 2022
Assignee:
Emory University
Inventors:
Paul Spearman, Karnail Singh, Xuemin Chen
Abstract: Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
May 17, 2022
Assignee:
Valneva Austria GmbH
Inventors:
Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
Abstract: The compositions and methods are described for generating an immune response to a Plasmodium antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to malaria by expressing the Plasmodium antigen in the subject to which the MVA vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat malaria.
Type:
Grant
Filed:
September 18, 2018
Date of Patent:
April 26, 2022
Assignee:
Geovax, Inc.
Inventors:
Farshad Guirakhoo, Arban Domi, Nathanael Paul McCurley
Abstract: Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention.
Abstract: The disclosure is directed to a device for electroporating and delivering one or more antigens and a method of electroporating and delivering one or more antigens to cells of epidermal tissues using the device. The device comprises a housing, a plurality of electrode arrays projecting from the housing, each electrode array including at least one electrode, a pulse generator electrically coupled to the electrodes, a programmable microcontroller electrically coupled to the pulse generator, and an electrical power source coupled to the pulse generator and the microcontroller. The electrode arrays define spatially separate sites.
Type:
Grant
Filed:
April 24, 2020
Date of Patent:
April 5, 2022
Assignee:
Inovio Pharmaceuticals, Inc.
Inventors:
Kate Broderick, Jay McCoy, Stephen V. Kemmerrer
Abstract: Provided herein is a method for producing an inactivated virus including a) heating the virus to a temperature sufficient to disrupt the virus membrane; b) exposing the virus of step (a) to an RNA degrading enzyme; and c) cooling the virus to a temperature sufficient to reestablish the integrity of the virus membrane. Also provided herein is a vaccine produced using the instant method.
Abstract: The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
March 8, 2022
Assignee:
Oregon Health & Science University
Inventors:
Louis Picker, Jay A. Nelson, Klaus Frueh, Michael A. Jarvis, Scott G. Hansen
Abstract: The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable exctpients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.
Abstract: Embodiments of the present invention provide compositions and methods for recombinantly generating tagless constructs of proteins or peptides. In certain embodiments, recombinant proteins or peptides disclosed herein concern human papilloma virus (HPV). Other embodiments concern using these constructs in compositions to elicit immune responses in a subject to one or more HPV types. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infections are also disclosed. Nucleic acids and expression vectors coding for constructs contemplated herein are provided. In certain embodiments, an HPV capsid protein generated is devoid of any fusion tags. In addition, truncated forms of HPV L1 are contemplated.
Type:
Grant
Filed:
August 2, 2019
Date of Patent:
November 30, 2021
Assignee:
The Regents of the University of Colorado, A Body Corporate
Abstract: (Technical problems to be solved) Providing a method for selecting an mineral of molybdenum. (Means for solving the problems) A peptide comprising an amino acids sequence according the following formula (1) and/or (2): (1) (ALRKNMD-FCPQSETGWHYIV)-(LIVFA)-(HPWRK)-(TSNQ)-(TSNQ)-(LIVFA)-(TSNQ)-(TSNQ)-(LIVFA)-(FYW)-(LIVFA)-(HPWRK) (2) (LIVFA)-(RHK)-(TSNQ)-(LIVFA)-(LIVFA)-(TSNQ)-(LIVFA)-(LIVFA)-(LIVFA)-(RHK)-(RHK)-(HPW) wherein one amino acid is respectively selected from each group defined by paired parentheses.
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
November 9, 2021
Assignees:
SHIBAURA INSTITUTE OF TECHNOLOGY, JX NIPPON MINING & METALS CORPORATION
Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments, the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration.
Abstract: The present invention relates to a method for preparing viral vector-based compositions wherein the viral vector-based particles present in the composition have a particle size distribution with a polydispersity index (PDI) of less than 0.5, the method comprising the steps: (a) providing replication-deficient viral vectors; (b) providing a solution comprising at least one sugar and at least three different excipients selected from hydrophilic and amphiphilic excipients, wherein the excipients are characterized by polar, aliphatic, aromatic, negatively charged, and/or positively charged functional groups, and wherein the solution is further characterized by an excipient-sugar ratio of at least 1:2 (w/w); and (c) mixing the replication deficient viral vectors of step (a) with the solution of step (b).
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
Type:
Grant
Filed:
September 17, 2020
Date of Patent:
October 12, 2021
Assignee:
AVIXGEN INC.
Inventors:
Min Jung Kim, Jun Sub Choi, Hye Cheong Koo, Yi Yong Baek
Abstract: Provided are surprisingly effective methods for inactivating pathogens, and for producing highly immunogenic vaccine compositions containing an inactivated pathogen rendered noninfectious by exposure to a Fenton reagent, or by exposure to a Fenton reagent or a component thereof in combination with a methisazone reagent selected from the group consisting of methisazone, methisazone analogs, functional group(s)/substructure(s) of methisazone, and combinations thereof. The methods efficiently inactivate pathogens, while substantially retaining pathogen antigenicity and/or immunogenicity, and are suitable for inactivating pathogens, or for the preparation of vaccines for a wide variety of pathogens with genomes comprising RNA or DNA, including viruses and bacteria. Also provided are highly immunogenic inactivated vaccine compositions prepared by using any of the disclosed methods, and methods for eliciting an immune response in a subject by administering such vaccine compositions.
Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.
Type:
Grant
Filed:
July 7, 2017
Date of Patent:
October 5, 2021
Assignees:
Hawaii Biotech, Inc., Infectious Disease Research Institute
Abstract: Provided herein are methods of incorporating substitutions of specified residues into a filovirus GP in order to increase immunogenicity and/or broaden the cross-reactivity of the protective immune response against other filovirus members. Also provided herein are mutant filovirus GPs comprising such substitutions.
Type:
Grant
Filed:
March 27, 2017
Date of Patent:
October 5, 2021
Assignees:
INTEGRATED BIOTHERAPEUTICS, INC., INTEGRAL MOLECULAR, INC.
Inventors:
Mohammad Javad Aman, Katie A. Howell, Edgar Davidson, Benjamin J. Doranz
Abstract: The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV.
Type:
Grant
Filed:
December 22, 2017
Date of Patent:
July 20, 2021
Assignee:
Intervet, Inc.
Inventors:
Theodorus Jansen, Maarten Hendrik Witvliet
Abstract: Disclosed herein a unique cell line system to generate a novel bovine adenovirus vector that provides more gene insertion capabilities and better immunogenicity for inserted antigens. The unique cell line is used for generating and growing of the new adenovirus vectors for gene delivery or recombinant vaccine production.
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
Type:
Grant
Filed:
April 3, 2018
Date of Patent:
March 23, 2021
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
Abstract: A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.
Type:
Grant
Filed:
December 7, 2015
Date of Patent:
March 16, 2021
Assignee:
Seqirus UK Limited
Inventors:
Christoph Haussmann, Frank Hauschild, Bjorn Jobst
Abstract: Provided are a mutated HPV58 L1 protein or a variant thereof, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein or a variant thereof and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types, and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
Abstract: A transdermal administration device including a first administration member including a first substrate and a first projection protruding from a first administration surface of the first substrate, and a second administration member including a second substrate and a second projection protruding from a second administration surface of the second substrate. The first substrate has an aperture, and the second substrate is positioned within the aperture when viewed in a direction perpendicular to the second administration surface.
Abstract: The present invention relates to methods and kits for detecting in a sample the presence of a virus particle or a virus-like particle that has reverse transcriptase activity and methods for preparing a retroviral contaminant-free substance. An aspect of the present invention is a method for detecting the presence of a virus particle in a sample of a Virus-like Particle (VLP) drug substance comprising a step of performing PCR-based reverse transcriptase (PBRT) on a sample of the VLP drug substance that has been treated with a protease.
Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.
Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
Type:
Grant
Filed:
March 29, 2019
Date of Patent:
December 15, 2020
Assignee:
The Government of the United States of America, as represented by the Secretary of Homeland Security
Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
Type:
Grant
Filed:
March 28, 2019
Date of Patent:
December 8, 2020
Assignee:
The Government of the United States of America, as represented by the Secretary of Homeland Security
Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
Type:
Grant
Filed:
March 28, 2019
Date of Patent:
December 8, 2020
Assignee:
The Government of the United States of America, as represented by the Secretary of Homeland Security
Abstract: The present invention provides methods for producing and/or expanding tumor-infiltrating lymphocytes (TILs) that can be used in adoptive immunotherapy in cancer treatment.
Type:
Grant
Filed:
December 15, 2015
Date of Patent:
December 8, 2020
Assignee:
UNIVERSITÉ DE LAUSANNE
Inventors:
Marie-Agnes Doucey, Nicolas Guex, Isaac Crespo, Ioannis Xenarios
Abstract: The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizing antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins. Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
November 3, 2020
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
James J. Mond, Clifford M. Snapper, Xinle Cui
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
Type:
Grant
Filed:
August 29, 2019
Date of Patent:
November 3, 2020
Assignee:
AVIXGEN INC.
Inventors:
Min Jung Kim, Jun Sub Choi, Hye Cheong Koo, Yi Yong Baek
Abstract: An oral vaccine composition for fish, and related oral vaccine delivery system and methods for making and using such oral vaccine composition and delivery system are described. The oral vaccine composition includes virus-like particles effective to mediate an immunoprotective response in a target fish species, wherein the virus-like particles are contained in biomass of an organism or cell culture in which the virus-like particles have been expressed, optionally further including (i) adjuvant effective to enhance the immunoprotective response of the virus-like particles in the target fish species; (ii) encapsulant protectively associated with the virus-like particles for selective locus bioavailability in the target fish species; and/or (iii) binding agent aggregating the ingredients of the composition with one another.
Type:
Grant
Filed:
December 31, 2018
Date of Patent:
October 6, 2020
Assignees:
UNIVERSITY OF MARYLAND BALTIMORE COUNTY, ALLOTROPIC TECH, LLC
Abstract: The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided.
Abstract: A non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) is provided herein, and methods of making and using the non-naturally occurring PRRSV also are provided.
Type:
Grant
Filed:
August 3, 2018
Date of Patent:
August 11, 2020
Assignees:
NUtech Ventures, The Board of Trustees of the University of Illinois
Inventors:
Hiep Lai Xuan Vu, Fernando Osorio, William W. Laegreid, Asit K. Pattnaik, Fangrui Ma
Abstract: The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.
Type:
Grant
Filed:
August 14, 2018
Date of Patent:
August 4, 2020
Assignee:
Deuteria Beverages, LLC
Inventors:
Anthony W. Czarnik, Jeffrey A. McKinney
Abstract: Aspects of the invention provide therapeutic recombinant protein preparations and methods of preparing therapeutic recombinant protein, which methods include contacting recombinant protein preparations with zwitterionic detergent at or above critical micelle concentration of the detergent.
Abstract: The disclosure is directed to a device for electroporating and delivering one or more antigens and a method of electroporating and delivering one or more antigens to cells of epidermal tissues using the device. The device comprises a housing, a plurality of electrode arrays projecting from the housing, each electrode array including at least one electrode, a pulse generator electrically coupled to the electrodes, a programmable microcontroller electrically coupled to the pulse generator, and an electrical power source coupled to the pulse generator and the microcontroller. The electrode arrays define spatially separate sites.
Type:
Grant
Filed:
February 1, 2018
Date of Patent:
June 2, 2020
Assignee:
Inovio Pharmaceuticals, Inc.
Inventors:
Kate Broderick, Jay McCoy, Stephen V. Kemmerrer
Abstract: Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.
Abstract: The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.
Type:
Grant
Filed:
November 2, 2017
Date of Patent:
May 26, 2020
Inventors:
Troy James Kaiser, Jeremy Kroll, Eric Martin Vaughn
Abstract: The present invention relates to a protein comprising a truncated version of the HSV-2 protein mg G-2, said protein comprising: (i) an extracellular region of mg G-2 (EX-mg G-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3; (ii) a truncated transmembrane region of mg G-2 (t-TMR-mg G-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and (iii) an intracellular region of mg G-2 (IC-mg G-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90% or 95% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.
Abstract: The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the immunodetection methods described above.
Type:
Grant
Filed:
March 25, 2016
Date of Patent:
April 14, 2020
Assignees:
VANDERBILT UNIVERSITY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
James E. Crowe, Jr., Andrew I. Flyak, Alexander Bukreyev, Philipp Ilinykh